Looking for income? You might want to check out Pfizer (NYSE: PFE). This big drugmaker has been a favorite for income investors for years. However, its dividend is arguably more attractive than ever.

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4. Analysts expect the health care company to report quarterly earnings at 64 cents ...

Here's some good news, though: Stock investors need to look forward much more than backward. Trailing returns are in the past. What matters most for current Pfizer investors and would-be Pfizer ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q3 2025 earnings on Oct. 28. Wall Street analysts expect ...

One of the most appealing features of Pfizer's stock is its dividend. The payout recently yielded a hefty 7.4% -- and it's been growing over time. There's reason to be bullish over Pfizer's long-term ...

KALAMAZOO, Mich. -- Even though U.S. health officials authorized the emergency use of Pfizer's COVID-19 vaccine, getting the pandemic under control will take time and effort. One of the biggest steps ...

UnitedHealth's Optum Rx makes money on the "spread" — the difference between the list price and the net price after rebates. But what happens if TrumpRx and MFN pricing collapse that spread? Fewer ...